ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

PURPOSE: In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO). METHODS: Women who completed ABL or PBO treatment in ACTIVE were eligible to receive up to 24 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Bone, Henry G, Cosman, Felicia, Miller, Paul D, Williams, Gregory C, Hattersley, Gary, Hu, Ming-yi, Fitzpatrick, Lorraine A, Mitlak, Bruce, Papapoulos, Socrates, Rizzoli, René, Dore, Robin K, Bilezikian, John P, Saag, Kenneth G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2018
Materias:
Clinical Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097601/
https://www.ncbi.nlm.nih.gov/pubmed/29800372
http://dx.doi.org/10.1210/jc.2018-00163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097601/
https://www.ncbi.nlm.nih.gov/pubmed/29800372
http://dx.doi.org/10.1210/jc.2018-00163

Ejemplares similares